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Abstract
Background: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in
elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably
considered the most widely accepted standard of treatment.
Methods: We retrospectively reviewed compliance and safety of adjuvant CMF in patients older than 60. The
treatment was indicated if patients had no severe comorbidity, a high-risk of recurrence, and were younger than
75. Toxicity was coded by NCI-CTC. Toxicity and compliance were compared between two age subgroups (<65,
≥ 65) by Fisher exact test and exact Wilcoxon rank-sum test.
Results: From March 1991 to March 2002, 180 patients were identified, 100 older than 60 and younger than 65,
and 80 aged 65 or older. Febrile neutropenia was more frequent among older patients (p = 0.05). Leukopenia,
neutropenia, nausea, cardiac toxicity and thrombophlebitis tended to be more frequent or severe among
elderlies, while mucositis tended to be more evident among younger patients, all not significantly. Almost one half
(47%) of the older patients receiving concomitant radiotherapy experienced grade 3–4 haematological toxicity.
Compliance was similar in the two groups, with 6 cycles administered in 86% and 79%, day-8 chemotherapy
omitted at least once in 36% and 39%, dose reduction in 27% and 38%, prolonged treatment duration (≥ 29 weeks)
in 10% and 11% and need of G-CSF in 9% and 18%, among younger and older patients, respectively.
Conclusion: Our data show that, in a highly selected population of patients 65 or more years old, CMF is as
feasible as in patients older than 60 and younger than 65, but with a relevant burden of toxicity. We suggest that
prospective trials in elderly patients testing less toxic treatment schemes are mandatory before indicating adjuvant
chemotherapy to all elderly patients with significant risk of breast cancer recurrence.
Published: 24 March 2005
BMC Cancer 2005, 5:30 doi:10.1186/1471-2407-5-30
Received: 02 December 2004
Accepted: 24 March 2005
This article is available from: http://www.biomedcentral.com/1471-2407/5/30
© 2005 De Maio et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2005, 5:30 http://www.biomedcentral.com/1471-2407/5/30
Page 2 of 10
(page number not for citation purposes)
Background
Breast cancer is a very frequent malignancy among elderly
patients. Its incidence increases with age, up to 80 years of
age [1]. Furthermore, there are convincing data from the
Surveillance, Epidemiology, and End Result (SEER) Pro-
gram [2] showing that the proportion of elderly patients
with breast cancer has been increasing during the last dec-
ades; patients aged 65 or more, indeed, accounted for
37% of breast cancer cases diagnosed in 1973 and for 47%
of those diagnosed in 1995.
Nowadays, adjuvant chemotherapy for breast cancer is a
standard clinical practice. This strategy has solid bases in
the data of the Oxford Overview by the Early Breast Can-
cer Trialists' Collaborative Group [3] that showed une-
quivocal benefit of adjuvant chemotherapy and suggested
that its positive effect could be additive to that of
tamoxifen. Thus, during recent years there has been a
trend toward giving chemotherapy to the majority of
women with early breast cancer, including the elderly
ones if their risk of relapse is high and their clinical condi-
tions are not deteriorated; thus, without considering eld-
erly patients like a special subgroup for which specific
recommendations are needed [4-6]. However, data col-
lected in the Overview do not directly demonstrate the
usefulness of adjuvant chemotherapy in older patients.
Larger number of patients are needed, possibly enrolled
into clinical trials specifically planned for elderly women,
like the recently published study conducted by the French
Adjuvant Study Group [7]. This study, indeed, evaluated
the efficacy of the addition of weekly epirubicin to
tamoxifen for patients older than 65 with node-positive
early breast cancer, finding an advantage in terms of dis-
ease-free survival for patients receiving chemotherapy.
Studies like this are needed to make the evidence stronger
and to overcome selection biases possibly deriving from
severe selection of elderly patients entered in clinical trials
designed for adult ones. Indeed, it is well known that the
proportion of elderly patients enrolled in clinical trials is
far more lower than the proportion they represent in pop-
ulation statistics [8], barriers to their enrollment being
multidimensional [9].
In clinical practice another problem due to the lack of reli-
able trials is the choice of which type of chemotherapy can
be given to elderly patients. While it is now recognized [6]
that two general levels of cytotoxic therapy regimens exist,
one less aggressive that includes four courses of doxoru-
bicin and cyclophosphamide or six courses of classical
CMF (cyclophosphamide, methotrexate and fluorour-
acil), and another more aggressive including cyclophos-
phamide, epirubicin, and fluorouracil [10,11] and
experimental associations or sequences with taxanes
[12,13], many of these schemes have never been tested in
prospective trials in elderly patients. With paucity of
experimental data, CMF is felt as the more reasonable
standard schedule for such patients [14].
While planning a randomized clinical trial, we reviewed
the records of early breast cancer patients who received
adjuvant CMF (days 1 and 8 every 4 weeks for a planned
number of 6 cycles) at the National Cancer Institute of
Naples, Italy, during the last decade, to describe compli-
ance and toxicity in patients 65 or more years old; as a
comparative group, we collected data of patients of the
immediately lower age cohort (older than 60 and younger
than 65).
Methods
We selected charts of patients older than 60 (i.e.: those
diagnosed breast cancer after the 60th birthday) who had
received CMF from March 1991 to March 2002, outside
clinical trials. All the patients had undergone mastectomy
or quadrantectomy plus axillary lymphadenectomy.
Patients undergoing conservative surgery were scheduled
for radiotherapy of the residual breast with a standard
scheme (5000 cGy plus 1000 cGy of boost on the quad-
rant) that was planned either concomitantly with adju-
vant chemotherapy or immediately after the end of it,
according to waiting lists or patient's or physician's prefer-
ence. When radiotherapy was planned concomitantly, it
was administered between the 3rd and the 4th cycle of
CMF, in a sandwich scheme, producing a 6 weeks prolon-
gation of the overall duration of CMF treatment.
In the period of interest, at our Institution, criteria on
which therapeutic decisions regarding adjuvant chemo-
therapy were taken outside clinical trials varied according
to the evolution of international guidelines and the results
of the Oxford metanalysis. Overall, we recommended
chemotherapy to patients aged less than 75, who had
undergone surgical treatment (mastectomy or quadran-
tectomy, plus axillary lymphnode dissection), with a high
risk of recurrence (based on common features like posi-
tive nodes, large primary tumor, high grade of malig-
nancy, estrogen-receptor negative), good performance
status (ECOG PS 0 or 1), normal function of vital organs
(bone marrow, kidney, liver and heart) and no other
severe comorbidity contraindicating chemotherapy. As
older the patients and as lower the estimate of recurrence
risk, the higher was the chance of choosing CMF rather
than an anthracycline-containing regimen. Estrogen
receptor positive patients, treated with chemotherapy,
received tamoxifen after the end of chemotherapy.
For this analysis, we focused on patients aged over 60,
who had received CMF according to the following sched-
ule: cyclophosphamide 600 mg/m2, methotrexate 40 mg/
m2 and fluorouracil 600 mg/m2, on days 1 and 8, every 4
weeks, for 6 planned cycles. With this schedule, commonBMC Cancer 2005, 5:30 http://www.biomedcentral.com/1471-2407/5/30
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supportive care was applied consisting of antiemetic med-
ication with 5HT3 antagonist on the days of chemo, anti-
biotics in case of known bacterial infection associated
with granulocyte colony-stimulating factor (G-CSF) in
case of febrile neutropenia; G-CSF was also sporadically
used in case of grade 4 neutropenia without fever, and
prophylactically in cycles following febrile or grade 4
neutropenia.
Pre-chemotherapy evaluation included medical history,
physical examination, haematology, serum biochemistry
tests, and tumor staging with chest radiography, abdomi-
nal ultrasonography, nuclidic bone scan with X-ray of
bone hot-spots, ECG and, in selected cases, an evaluation
of left ventricular ejection fraction. Toxicity was usually
assessed with blood counts preceding each administration
of chemotherapy, and complete serology before day 1
administration of chemotherapy, unless clinical need for
more frequent control. Reviewing the charts, we codified
toxicity according to National Cancer Institute Common
Toxicity Criteria (version 2.0, 1998). Toxicity is reported
with details of type and grade, including all grades. Any-
way, for descriptive purposes we also summarised toxicity
into three major groups: haematological (leukopenia,
neutropenia, anemia, thrombocytopenia, febrile neutro-
penia, bleeding, infection), other (including all the other
toxicities) and any (including both haematological and
other) and we summed up grades 0 to 2 as non severe and
grades 3 or 4 as severe.
To analyse compliance, the distribution of several indices
was compared between the two age subgroups. A cycle
was considered as delivered if day 1 chemotherapy had
been administered. Indices used for compliance descrip-
tion were: a) the number of delivered cycles, b) the occur-
rence of withdrawal of chemotherapy on day 8, c) the
occurrence and the percentage of dose-reductions, d) the
occurrence of treatment delay that was expressed as rela-
tive duration by dividing actual and planned duration (1
means no delay, higher values mean progressively longer
delays), e) the need for G-CSF treatment according to pre-
viously reported guidelines, and f) the cause of treatment
discontinuation if earlier than planned. After description
of single indices, a binary index was built, weak compli-
ance being defined as the occurrence of at least one of the
following events: less than 6 cycles administered, with-
drawal of more than one day-8 treatment, dose reduction
in more than 25% of cycles, relative duration higher than
1.25, need of G-CSF treatment, treatment interruption
because of patient's refusal or toxicity. Because of possible
confounding effect of radiotherapy associated to CMF,
both toxicity and compliance were analysed not only by
age subgroups but also according to presence or absence
of concomitant radiotherapy.
Disease-free survival was defined as the time elapsed from
surgery to the date of assessment of local or distant or con-
tralateral breast cancer or the date of death for patients
dying without disease recurrence. The Kaplan-Meier
method was applied to draw disease-free survival curves.
Statistical significance of associations among variables
was tested by the Fisher's exact test, or Wilcoxon-Mann
Whitney test for naturally ordered variables (i.e. number
of cycles, no. of day 8 omitted, grades of toxicity). Disease-
free survival curves were compared by the Log-rank test.
Analysis were done with S-PLUS (6.0 Professional Release
1, Insightful Corporation) and StatXact-5 (release 5.0.3,
Cytel software Corporation).
Table 1: Characteristics of Patients (N = 180)
Median age (range), yrs 64 (60–73)
Age category, n (%)
>60 and < 65 years 100 (56)
≥ 65 years 80 (44)
pT-category, n (%)
pT1 73 (41)
pT2 91 (51)
pT3 5 (3)
pT4 3 (2)
unknown 8 (4)
pN-category, n (%)
pN0 66 (37)
pN1 97 (54)
pN2 10 (6)
unknown 7 (4)
Receptor status, n (%)
ER or PgR positive 82 (46)
Negative 78 (43)
Unknown 20 (11)
Histotype, n (%)
Ductal 132 (73)
Lobular 33 (18)
Other 15 (8)
Histologic grade, n (%)
G1 5 (3)
G2 53 (29)
G3 96 (53)
Unknown 26 (14)
Concomitant radiotherapy, n (%)
No 114 (63)
Yes 66 (37)BMC Cancer 2005, 5:30 http://www.biomedcentral.com/1471-2407/5/30
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Results
From March 1991 to March 2002, 180 patients were iden-
tified, 80 aged 65 or older, and 100 older than 60 and
younger than 65. The baseline characteristics of patients
are reported in table 1. Overall, 87 patients received radi-
otherapy on the residual breast; among these, 21 patients,
who received radiation therapy after the end of CMF, have
been considered in the no radiotherapy subgroup for all
subsequent analyses. Sixty-six patients receiving concom-
itant radiotherapy were equally distributed in the two age
subgroups, 36 (36%) being younger than 65 and 30
(38%) being older.
Treatment toxicity scattered by age subgroups is reported
in table 2. There was no toxic death. The only type of tox-
icity that significantly differed between the two age groups
was febrile neutropenia that occurred in 3 cases among
older patients and never in the younger group (p = 0.05).
Among toxicities that did not show a statistically signifi-
cant difference between the two groups, leukopenia, neu-
tropenia, nausea, cardiac toxicity and thrombophlebitis
tended to be more frequent or severe among elderlies,
while mucositis tended to be more evident among
younger patients. As shown in table 3, haematologic tox-
icity was adversely affected by concomitant radiotherapy,
leukopenia, neutropenia, febrile neutropenia and fever
being significantly worse among patients who received
concomitant radiotherapy. As reported in table 4, inci-
dence of grade 3–4 toxicity (either haematological or
other or any type) did not vary according to age, while
severe haematological toxicity was more frequent among
patients who received concomitant radiotherapy (35% vs
8%, p < 0.0001); almost one half (47%) of the older
patients receiving concomitant radiotherapy experienced
grade 3–4 hematological toxicity.
Focusing on compliance, we found that CMF scheduling
was modified (from days 1 and 8 every 4 weeks to day 1
every 3 weeks) because of toxicity in 7 patients (2 in the
older and 5 in the younger group, p = 0.46); none of these
Table 2: Worst degree of toxicity by age group (% of patients)
Type of toxicity >60 and <65 years (n = 100) ≥ 65 years (n = 80) P*
01 2 3 4 01 23 4
Anemia 81 10 8 0 1 86 6 4 4 0 0.39
Leukopenia 54 15 19 7 5 45 11 26 11 6 0.13
Neutropenia 73 10 8 5 4 68 9 7 10 6 0.32
Febrile Neutropenia 100 - - 0 0 96 - - 4 0 0.05
Infection 97 0 1 2 0 95 0 2.5 2.5 0 0.50
F e v e r 9 8020 0 9 820 0 0 0.83
Thrombocytopenia 90 7 2 0 1 91 4 1 3 1 0.83
Bleeding 98 1 0 1 0 100 0 0 0 0 0.21
Nausea 81 8 6 5 0 69 11 12 8 0 0.06
Vomiting 71 5 11 13 0 69 9 16 6 0 0.98
Mucositis 84 5 8 3 0 92 1 5 1 0 0.09
Skin 99 1 0 0 0 98 0 2 0 0 0.43
Diarrhea 96 1 0 3 0 96 3 1 0 0 0.91
Constipation 99 0 0 1 0 98 1 1 0 0 0.45
H e p a t i c 8 8372 0 9 064 0 0 0.60
Cardiac 100 0 0 0 0 96 0 2.5 1 0 0.09
F a t i g u e 9 6130 0 9 50 2 . 5 2 . 5 0 0.72
Pulmonary 100 0 0 0 0 99 1 0 0 0 0.27
Abdominal pain 99 0 0 1 0 99 0 0 1 0 0.88
Chest pain 99 0 0 1 0 100 0 0 0 0 0.37
H e a r t b u r n 9 9010 0 9 802 0 0 0.44
Headache 99 0 0 1 0 100 0 0 0 0 0.38
Confusion 99 1 0 0 0 100 0 0 0 0 0.38
Depression 100 0 0 0 0 99 0 0 1 0 0.27
Thrombophlebitis 97 0 0 3 0 94 0 0 6 0 0.30
D y s u r i a 9 9001 0 9 900 1 0 0.88
Allergy 99 0 0 1 0 100 0 0 0 0 0.37
Weight gain 100 0 0 0 0 99 0 1 0 0 0.27
Weight loss 99 0 1 0 0 99 1 0 0 0 0.89
* Wilcoxon-Mann Whitney testBMC Cancer 2005, 5:30 http://www.biomedcentral.com/1471-2407/5/30
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patients did receive concomitant radiotherapy (p = 0.05).
Distribution of compliance indices is summarized in table
5. Seventy-six percent of older patients received six cycles
of chemotherapy as compared with 81% of those in the
younger group. Day 8 of chemotherapy was withdrawn at
least once in 36% and 31%, and 18% and 14% of the
patients had more than 25% of cycle at reduced doses, in
the older and younger groups, respectively. Treatment was
administered without significant delay (i.e. 24 weeks
without concomitant radiotherapy or 30 weeks with) in
almost all the patients. Haematopoietic support with G-
CSF was required by 18% and 9% of older and younger
patients. Causes of treatment discontinuation were simi-
lar in the two groups, protocol completion accounting for
more than three-fourths, and refusal and toxicity for
about 10% each (p = 0.39). Eighty-eight percent of the 66
patients who received concomitant radiotherapy were
able to receive 6 cycles of CMF and completed treatment
according to the protocol, as compared with 74% of those
not irradiated concomitantly; concomitant irradiation
prolonged significantly duration of CMF in 5% of patients
and produced a more frequent need of G-CSF. Overall, a
weak compliance (i.e. the occurrence of at least one of the
following events: less than 6 cycles received, more than 1
day 8 omission, dose reduction in more than 25% of
cycles, relative duration higher than 1.25, use of G-CSF or
treatment interruption because of toxicity or refusal) was
more frequent among older patients (58% vs 46%, p =
0.02) and did not vary according to concomitant
radiotherapy.
Table 3: Worst degree of hematological toxicity by radiotherapy (% of patients)
Type of toxicity No (n = 114) Yes (n = 66) P*
0 1 23 40 1 2 3 4
Anemia 87 6 4 3 0 77 12 9 0 1.5 0.12
Leukopenia 58 15 22 3 3 36 11 23 20 11 0.0001
Neutropenia 82 8 6 2 2 50 12 11 17 11 <0.0001
Febrile Neutropenia 100 0 0 0 0 95 0 0 5 0 0.05
Infection 96 0 2 2 0 95 0 2 3 0 0.89
Fever 100 0 0 0 0 94 6 0 0 0 0.02
Thrombocytopenia 90 6 2 1 1 91 4.5 1.5 1.5 1.5 0.96
Bleeding 99 0 0 1 0 98 2 0 0 0 1.00
* Wilcoxon-Mann Whitney test
Table 4: Summary of toxicity by age, radiotherapy and combined subgroups expressed as row percentages)
Haematologic Other Any
Subgroup G0-2 G3-4 p* G0-2 G3-4 p* G0-2 G3-4 p*
Age 0.17 0.49 1.00
>60 and <65 years (n = 100) 86% 14% 72% 28% 62% 38%
≥ 65 years (n = 80) 78% 22% 78% 22% 61% 39%
Radiotherapy <0.0001 0.21 0.27
No (n = 114) 92% 8% 71% 29% 65% 35%
Yes (n = 66) 65% 35% 80% 20% 56% 44%
Age and radiotherapy <0.0001 0.42 0.08
>60 and < 65, no RT (n = 64) 92% 8% 67% 33% 59% 41%
≥ 65, no RT (n = 50) 92% 8% 76% 24% 72% 28%
>60 and < 65, RT (n = 36) 75% 25% 81% 19% 67% 33%
≥ 65, RT (n = 30) 53% 47% 80% 20% 43% 57%
G = grade; RT = radiotherapy.BMC Cancer 2005, 5:30 http://www.biomedcentral.com/1471-2407/5/30
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As of March 2004, 41 patients had an event and disease-
free survival at 5 and 8 years was 76% and 71%. As shown
in figure 1, there was no statistically significant difference
in disease-free survival in the two age groups (p = 0.84).
Discussion
The present study was planned being aware that a selec-
tion bias, typical of retrospective data collection, could
affect the results; namely, outside clinical trials, the
therapeutic strategy applied in our Institution during the
time period of interest for this study was prevalently
conservative, foreseeing adjuvant chemotherapy in elderly
patients when either a very high risk of relapse or a very
strong patient's motivation existed, no severe or untreata-
ble comorbid conditions being evident. Overall, we antic-
ipated that, under such conditions and because of
selection bias, our study should produce underestimation
of toxicity and lack of compliance, this effect possibly
being as more pronounced as older the patients because
of the application of more restrictive criteria.
Table 5: Pattern of compliance to chemotherapy by age and radiotherapy
Variable Age Radiotherapy
>60 and < 65 (n = 100) ≥ 65 (n = 80)P § No* (n = 114)Y e s  ( n = 66)P §
N. of cycles administered, no. (%) 0.42 0.01
6 cycles 81 (81) 61 (76) 84 (74) 58 (88)
5 cycles 5 (5) 4 (5) 4 (3) 5 (8)
4 cycles 4 (4) 4 (5) 6 (5) 2 (3)
3 cycles 5 (5) 6 (8) 10 (9) 1 (1)
2 cycles 4 (4) 4 (5) 8 (7) 0
1 cycle 1 (1) 1 (1) 2 (2) 0
N. of day 8 omitted, no. (%) 0.37 0.86
0 69 (69) 51 (64) 77 (68) 43 (65)
1 23 (23) 18 (22) 24 (21) 17 (26)
2 5 (5) 8 (10) 9 (8) 4 (6)
3 3 (3) 3 (4) 4 (3) 2 (3)
Rate of cycles at reduced dose, no. (%) 0.54 0.83
≤ 25% 86 (86) 66 (82) 97 (85) 55 (83)
>25% 14 (14) 14 (18) 17 (15) 11 (17)
Actual/planned duration, no. (%) 0.59 0.05
≤ 1.25 99 (99) 78 (98) 114 (100) 63 (95)
>1.25 1 (1) 2 (2) 0 3 (5)
G-CSF utilization, no. (%) 0.12 <.0001
No 91 (91) 66 (82) 109 (96) 48 (73)
Yes 9 (9) 14 (18) 5 (4) 18 (27)
Treatment discontinuation, no. (%) 0.52 0.10
protocol completion 81 (81) 61 (76) 84 (74) 58 (88)
patient's refusal 6 (6) 9 (11) 12 (11) 3 (4)
treatment toxicity 11 (11) 7 (9) 13 (11) 5 (8)
other 2 (2) 3 (4) 5 (4) 0
Low compliance†, no. (%) 0.02 0.88
No 61 (61) 34 (42) 61 (54) 34 (52)
yes 39 (39) 46 (58) 53 (46) 32 (48)
* including 21 patients who received radiotherapy after the end of chemotherapy
§ Fisher exact test or Wilcoxon-Mann Whitney test for naturally ordered variables)
† at least one of the following features: less than 6 cycles administered, withdrawal of more than one day-8 treatment, dose reduction in more than 
25% of cycles, relative duration higher than 1.25, use of G-CSF treatment, treatment interruption because of patient's refusal or toxicityBMC Cancer 2005, 5:30 http://www.biomedcentral.com/1471-2407/5/30
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We selected for this study a consecutive series of 180 early
breast cancer patients aged 60 to 73 that received, outside
clinical trials, adjuvant CMF, with all drugs intravenously
on days 1 and 8 every 4 weeks for 6 cycles; this schedule
resulted as the most commonly used regimen in a survey
circulated among the members of the Breast International
Group [14]. Overall, 18% of the patients suffered grade 3–
4 toxicity, and 47% had some problem of compliance,
either because dosing and scheduling rules could not be
followed appropriately, or because costly supportive
drugs (G-CSF) were required. Both these figures are much
higher than what we expected. In addition, problems were
more frequent among the older subgroup (for compli-
ance) and when radiotherapy was given concomitantly
with CMF (for haematological toxicity). The sense of such
finding is even strengthened by the fact that very old
patients, i.e. those over 75, were not considered for treat-
ment. Particularly, concomitant radiotherapy signifi-
cantly prolonged duration of chemotherapy over the
planned time in 5% of patients, haematological toxicity
being the most reasonable cause, as suggested by a more
frequent need of G-CSF. Paradoxically, because of more
prolonged time and less intensive administration, the
number of CMF cycles fared better among patients who
received concomitant radiotherapy.
In a retrospective analysis of adjuvant CMF for elderly
breast cancer patients enrolled in the International Breast
Cancer Study Group (IBCSG) trial VII [15], 76 women 65
years of age or older, compared with 223 postmenopausal
women younger than 65, showed higher grades of severe
toxicity either considering any type (17% v 7%, respec-
tively), or haematologic (9% v 5%, respectively). In addi-
tion, only 48% of the older patients as compared with
Kaplan-Meier estimated disease-free survival curves by age categories (solid line: >60 and <65 years; dashed line: ≥ 65 years;  crosses indicate censoring) Figure 1
Kaplan-Meier estimated disease-free survival curves by age categories (solid line: >60 and <65 years; dashed line: ≥ 65 years; 
crosses indicate censoring)
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65% of the younger ones received at least 85% of the
planned dose. Our findings in terms of toxicity and com-
pliance are overall worse than in the IBCSG trial VII. The
most reasonable explanation for this is the duration of
CMF, that was planned for 3 cycles in the IBCSG trial and
for 6 cycles in our routine practice; also, we cannot
exclude effects of the type of schedule (all drugs intrave-
nously versus cyclophosphamide orally on days 1–14)
and the effect of the timing of radiotherapy, given at the
end of chemotherapy in the IBCSG trial VII, while it was
concomitant in 37% of the patients in our study. In addi-
tion, we hypothesize that selection bias, arising from typ-
ical exclusion criteria of randomized clinical trials, could
also have lowered toxicity rate in the IBCSG trial VII. Any-
way, the conclusion of the Authors that less toxic chemo-
therapy regimens are required for high-risk elderly
patients is completely supported by our findings.
For elderly patients with breast cancer, adjuvant chemo-
therapy should be considered both when the tumor does
not express hormonal receptors, because tamoxifen
would be ineffective, and in many cases in which the
tumor is receptor-positive, because several indirect, but
reliable, evidences suggest that positive effects of chemo-
therapy and tamoxifen are not mutually exclusive but can
sum up, at a given extent. Based on current knowledge, the
problem could be structured saying that the choice of not
giving adjuvant chemotherapy must be supported by valid
reasons, inside the decision making process. Factors that
can affect such decision are risk of relapse, life expectancy
and patient's preferences. As for risk of relapse, several
subsequent editions of the St.Gallen guidelines [4,6,16],
widely accepted as a reasonable approach to the treatment
of early breast cancer, rule out that patients with ER/PgR-
negative can be considered at minimal risk. In addition,
within endocrine responsive tumors, the minimal risk cat-
egory is limited to a quite small group of patients. A large
amount of elderly patients fall within prognostic catego-
ries at average or high risk of relapse. Extermann et al. [17]
faced the problem of coupling the risk of cancer relapse or
death with life expectancy in order to define a utility
measure that can assist decision making. Based on current
estimates of efficacy of adjuvant chemotherapy, they
found that a risk of 12% at 10 years is the threshold value
to produce an absolute 1% survival gain for a 75 years old
patient, who has approximately 12 years of life expect-
ancy, if not particularly sick; as for the risk of relapse,
estimates show that older breast cancer patients can
expect advantages from treatment fairly similar to that of
younger patients, both for tamoxifen and for chemother-
apy. Finally, patient's preferences are not an easy matter of
study [18], and, particularly in the setting of adjuvant
chemotherapy of elderly breast cancer patients, data are
very poor. Some studies, mostly including patients
younger than 70, have shown that age does not affect
patient's preferences [19] and that most patients consider
6 months of adjuvant CMF chemotherapy worthwhile for
relatively modest survival gains [20]. Furthermore, indi-
rect data, regarding elderly cancer patients [21] with vari-
ous cancer types, suggest that more than 70% of elderly
patients are willing to receive effective chemotherapy even
if toxicity is relevant; such data, however, should be con-
firmed in a particular clinical setting like that of adjuvant
chemotherapy, where the treatment is given to reduce an
invisible risk, rather than to cure a visible disease.
Anyway, while growing the scientific evidence that adju-
vant chemotherapy should be considered for elderly
patients with breast cancer at risk of relapse, several
reports show that the use of adjuvant chemotherapy in
clinical practice does dramatically decline with age. De
Michele et al. showed that in a tertiary cancer centre the
rate of women eligible for adjuvant chemotherapy accord-
ing to international guidelines who were actually offered
chemotherapy dramatically decreased from 77%, among
those aged 61 to 69, to 23%, among those aged 70 ore
more [22]. Mandelblatt et al., from the Outcomes and
Preferences for Treatment in Older Women Nationwide
Study (OPTIONS) project, reported that, within a cohort
of 718 patients, treated at public hospitals in several US
states between 1995 and 1997, only 7% of those aged 67
to 79 years received adjuvant chemotherapy [23].
Woodard et al., after adjusting for a number of possible
confounders, found that the odds of not receiving adju-
vant chemotherapy for patients older than 65 is 62 times
higher than that of patients younger than 50, and, even if
the analysis is limited to ER-negative cases (i.e. those not
amenable to hormonal adjuvant treatment), an odds of 7
is calculated [24].
There can be a lot of reasons for the discrepancy between
guidelines or clinical trials evidences and practical appli-
cation. One we believe is very important, together with
other Authors [25], is the paucity of clinical trials
specifically addressing adjuvant chemotherapy of elderly
patients, because it is conceivable that lack of reliable evi-
dences does not encourage physicians to suggest treat-
ments that are potentially toxic and dangerous [26]. The
consequences of such phenomenon are relevant, consid-
ering that sensible differences in patients outcome can be
produced by varying treatment approaches [27].
Conclusion
In conclusion, the present data, together with other retro-
spective evidences, strongly highlight the need of clinical
trials of adjuvant chemotherapy specific for elderly early
breast cancer patients, possibly looking for drugs or
schemes that have shown in previous feasibility studies a
favourable profile of safety. In this light, in a randomised
clinical trial open to early breast cancer patients aged 65BMC Cancer 2005, 5:30 http://www.biomedcentral.com/1471-2407/5/30
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to 80 with an average/high risk of relapse according to
St.Gallen criteria, we are actually comparing CMF with
weekly docetaxel, a treatment scheme that has shown suf-
ficient activity and excellent tolerability in a phase II study
conducted in elderly advanced breast cancer patients [28].
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